| Literature DB >> 32848427 |
Leila Ahmadian1,2, Mohammad Reza Haghshenas1,2, Bahman Mirzaei3, Zahra Norouzi Bazgir1,2, Hamid Reza Goli1,2.
Abstract
PURPOSE: The integrons, as the mobile exogenous elements, play a prominent role in the spreading of antimicrobial resistance genes from Pseudomonas aeruginosa clinical isolates to other bacteria. This study aimed to investigate the frequency of class 1 integrons andresistance gene cassettes carrying by them in clinical isolates as well as multidrug resistant P. aeruginosa.Entities:
Keywords: MDR; Pseudomonas aeruginosa; class 1 integrons; resistance gene cassettes
Year: 2020 PMID: 32848427 PMCID: PMC7429104 DOI: 10.2147/IDR.S263759
Source DB: PubMed Journal: Infect Drug Resist ISSN: 1178-6973 Impact factor: 4.003
The Comparison of Antibiotic Resistance Profile Between the Integron Positive and Negative Clinical Isolates of Pseudomonas aeruginosa
| Antibiotics | Total (n=100) | Integron Positive (n=42) | Integron Negative (n=58) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| R | I | S | R | I | S | R | I | S | ||
| AK | 28 | 13 | 59 | 19 | 5 | 18 | 9 | 8 | 41 | 0.0042 |
| GN | 41 | 5 | 54 | 26 | 2 | 14 | 15 | 3 | 40 | 0.0012 |
| TN | 39 | 1 | 60 | 25 | 0 | 17 | 14 | 1 | 43 | 0.0014 |
| CIP | 41 | 3 | 56 | 25 | 0 | 17 | 16 | 3 | 39 | 0.0034 |
| LEV | 43 | 3 | 54 | 26 | 1 | 15 | 17 | 2 | 39 | 0.0050 |
| ATM | 39 | 33 | 28 | 25 | 10 | 7 | 14 | 6 | 21 | 0.0039 |
| PTZ | 12 | 11 | 77 | 10 | 5 | 27 | 2 | 4 | 50 | 0.0052 |
| CPM | 32 | 5 | 63 | 21 | 1 | 20 | 11 | 4 | 43 | 0.0040 |
| CAZ | 27 | 2 | 71 | 16 | 1 | 25 | 11 | 1 | 46 | 0.0955 |
| PRL | 26 | 21 | 53 | 17 | 12 | 13 | 9 | 9 | 40 | 0.0007 |
| DOR | 28 | 11 | 61 | 22 | 3 | 17 | 6 | 8 | 44 | 0.0001 |
| IMI | 31 | 8 | 61 | 18 | 5 | 19 | 13 | 3 | 42 | 0.0222 |
| MEM | 37 | 5 | 58 | 26 | 0 | 16 | 11 | 5 | 42 | 0.0001 |
Note: All results in this table about the rate of resistance or susceptibility of the isolates are based on the percent.
Abbreviations: R, resistant; I, intermediate resistant; S, susceptible; AK, amikacin; GN, gentamicin; TN, tobramycin; CIP, ciprofloxacin; LEV, levofloxacin; ATM, aztreonam; PTZ, piperacillin-tazobactam; CPM, cefepime; CAZ, ceftazidime; PRL, piperacillin; DOR, doripenem; IMI, imipenem; MEM, meropenem.
The Comparison of Resistance Percent Rates Against 13 Tested Antibiotics Among the MDR and Non-MDR Isolates of Pseudomonas aeruginosa
| Antibiotics | MDR Isolates (n=41) | Non MDR Isolates (n=59) | |||||
|---|---|---|---|---|---|---|---|
| R | I | S | R | I | S | ||
| AK | 27 | 6 | 8 | 1 | 7 | 51 | < 0.0001 |
| GN | 39 | 1 | 1 | 2 | 4 | 53 | < 0.0001 |
| TN | 38 | 0 | 3 | 1 | 1 | 57 | < 0.0001 |
| CIP | 38 | 1 | 2 | 3 | 2 | 54 | < 0.0001 |
| LEV | 38 | 0 | 3 | 5 | 3 | 51 | < 0.0001 |
| ATM | 38 | 3 | 0 | 1 | 30 | 28 | < 0.0001 |
| PTZ | 12 | 11 | 18 | 0 | 0 | 59 | < 0.0001 |
| CPM | 32 | 3 | 6 | 0 | 2 | 57 | < 0.0001 |
| CAZ | 27 | 2 | 12 | 0 | 0 | 59 | < 0.0001 |
| PRL | 26 | 13 | 2 | 0 | 8 | 51 | < 0.0001 |
| DOR | 25 | 6 | 10 | 3 | 5 | 51 | < 0.0001 |
| IMI | 24 | 4 | 13 | 7 | 4 | 48 | < 0.0001 |
| MEM | 30 | 3 | 8 | 7 | 2 | 50 | < 0.0001 |
Abbreviations: R, resistant; I, intermediate resistant; S, susceptible; MDR, multi-drug resistance; AK, amikacin; GN, gentamicin; TN, tobramycin; CIP, ciprofloxacin; LEV, levofloxacin; ATM, aztreonam; PTZ, piperacillin-tazobactam; CPM, cefepime; CAZ, ceftazidime; PRL, piperacillin; DOR, doripenem; IMI, imipenem; MEM, meropenem.
The Prevalence of Different Resistance Gene Cassette Arrays in the Clinical Isolates of Pseudomonas aeruginosa and Their Correlation with the Resistance Towards Tested Antibiotics
| Length of IVRs | Gene Cassettes | No. of | (No.) of Isolates Which Were Resistant to | No. of |
|---|---|---|---|---|
| 0.6 | Hypothetical gene cassette | 1 | AK (1), GM (1), TN (1), CIP (1), LEV (1), ATM (1), PTZ (1), CPM (1), CAZ (0), PRL (1), DOR (1), IMI (1), MEM (1) | 1 |
| 0.75 | 7 | AK (2), GM (3), TN (3), CIP (3), LEV (3), ATM (3), PTZ (1), CPM (3), CAZ (3), PRL (2), DOR (2), IMI (2), MEM (4) | 3 | |
| 1.3 | 7 | AK (1), GM (2), TN (2), CIP (1), LEV (1), ATM (1), PTZ (0), CPM (2), CAZ (2), PRL (1), DOR (2), IMI (1), MEM (2) | 2 | |
| 1.7 | 1 | AK (0),GM (1), TN (1), CIP (1), LEV (1), ATM (1), PTZ (0), CPM (1), CAZ (1), PRL (1), DOR (0), IMI (0), MEM (0) | 1 | |
| 2.3 | 1 | AK (0), GM (0), TN (0), CIP (0), LEV (0), ATM (1), PTZ (0), CPM (0), CAZ (1), PRL (0), DOR (1), IMI (0), MEM (1) | 1 | |
| 2.5 | 3 | AK (2), GM (2), TN (2), CIP (2), LEV (2), ATM (2), PTZ (1), CPM (2), CAZ (0), PRL (0), DOR (2), IMI (1), MEM (2) | 2 | |
| 3.5 | 2 | AK (0), GM (2), TN (2), CIP (1), LEV (2), ATM (1), PTZ (0), CPM (0), CAZ (0), PRL (0), DOR (1), IMI (1), MEM (1) | 1 | |
| 0.6 + 1.7 | Hypothetical gene cassette + | 1 | AK (1), GM (1), TN (1), CIP (1), LEV (1), ATM (1), PTZ (0), CPM (1), CAZ (1), PRL (0), DOR (1), IMI (1), MEM (1) | 1 |
| 0.75 + 1.3 | 1 | AK (0), GM (0), TN (0), CIP (0), LEV (0), ATM (0), PTZ (0), CPM (0), CAZ (0), PRL (0), DOR (0), IMI (0), MEM (0) | 0 | |
| 0.75 + 1.7 | 2 | AK (2), GM (2), TN (1), CIP (2), LEV (2), ATM (2), PTZ (0), CPM (1), CAZ (1), PRL (0), DOR (1), IMI (2), MEM (2) | 2 | |
| 0.75 + 2.0 | 1 | AK (0), GM (1), TN (1), CIP (1), LEV (1), ATM (1), PTZ (0), CPM (1), CAZ (1), PRL (1), DOR (0), IMI (0), MEM (0) | 1 | |
| 0.75 + 2.3 | 3 | AK (3), GM (3), TN (3), CIP (3), LEV (3), ATM (3), PTZ (2), CPM (2), CAZ (1), PRL (3), DOR (3), IMI (3), MEM (3) | 3 | |
| 1.3 + 1.5 | 1 | AK (0), GM (0), TN (0), CIP (0), LEV (0), ATM (0), PTZ (0), CPM (0), CAZ (0), PRL (0), DOR (1), IMI (1), MEM (1) | 0 | |
| 1.3 + 1.7 | 1 | AK (1), GM (1), TN (1), CIP (1), LEV (1), ATM (1), PTZ (1), CPM (1), CAZ (1), PRL (1), DOR (1), IMI (1), MEM (1) | 1 | |
| 1.3 + 2.3 | 1 | AK (0), GM (1), TN (1), CIP (1), LEV (1), ATM (1), PTZ (0), CPM (0), CAZ (0), PRL (1), DOR (1), IMI (1), MEM (1) | 1 | |
| 1.5 + 3.0 | 1 | AK (1), GM (1), TN (1), CIP (1), LEV (1), ATM (1), PTZ (1), CPM (1), CAZ (0), PRL (1), DOR (1), IMI (0), MEM (1) | 1 | |
| 2.0 + 3.5 | 1 | AK (0), GM (0), TN (0), CIP (1), LEV (1), ATM (0), PTZ (0), CPM (0), CAZ (0), PRL (0), DOR (0), IMI (0), MEM (0) | 0 | |
| 0.75 + 1.3 + 1.5 | 1 | AK (1), GM (1), TN (1), CIP (1), LEV (1), ATM (1), PTZ (0), CPM (1), CAZ (1), PRL (1), DOR (0), IMI (0), MEM (1) | 1 | |
| 0.75 + 1.3 + 1.7 | 1 | AK (0), GM (0), TN (0), CIP (0), LEV (0), ATM (0), PTZ (0), CPM (0), CAZ (0), PRL (0), DOR (1), IMI (1), MEM (1) | 0 | |
| 0.75 + 1.3 + 2.5 | 2 | AK (1), GM (1), TN (1), CIP (1), LEV (1), ATM (1), PTZ (0), CPM (1), CAZ (1), PRL (1), DOR (0), IMI (0), MEM (1) | 1 | |
| 0.75 + 1.7 + 2.3 | 2 | AK (2), GM (2), TN (2), CIP (2), LEV (2), ATM (2), PTZ (2), CPM (2), CAZ (2), PRL (2), DOR (2), IMI (2), MEM (2) | 2 | |
| 1.7 + 2.3 + 3.0 | 1 | AK (1), GM (1), TN (1), CIP (1), LEV (1), ATM (1), PTZ (1), CPM (1), CAZ (0), PRL (1), DOR (1), IMI (0), MEM (1) | 1 | |
| Total | 69 gene cassettes | 42 | 26 |
Abbreviations: VR, variable regions; MDR, multi-drug resistance, AK, amikacin; GN, gentamicin; TN, tobramycin; CIP, ciprofloxacin; LEV, levofloxacin; ATM, aztreonam; PTZ, piperacillin-tazobactam; CPM, cefepime; CAZ, ceftazidime; PRL, piperacillin; DOR, doripenem; IMI, imipenem; MEM, meropenem.
Prevalence of MDR and Integron Positive Pseudomonas aeruginosa Clinical Isolates Based on the Source of Isolation
| Source of Isolates | No. (%) of | ||
|---|---|---|---|
| Total Isolates | MDR Isolates | Integron Positive Isolates | |
| Sputum | 37 (37) | 11 (29.72) | 16 (43.24) |
| Urine | 26 (26) | 7 (26.92) | 10 (38.46) |
| Wound | 20 (20) | 13 (65) | 10 (50) |
| Catheter | 8 (8) | 7 (87.5) | 4 (50) |
| Blood | 5 (5) | 2 (40) | 2 (40) |
| Others | 4 (4) | 1 (25) | 0 (0) |
Figure 1The number of integron positive and MDR Pseudomonas aeruginosa clinical isolates according to the hospital sources.
Figure 2The size and structure of resistance gene cassettes between two conserved ends (5′CS and 3′CS) of the class 1 integrons detected in the clinical isolates of Pseudomonas aeruginosa.